Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.45) per share. This is a 87.5 percent decrease over losses of $(0.24) per share from the same period last year.
JP Morgan Downgrades Vertiv Holdings to Neutral, Announces $25 Price Target
JP Morgan analyst Stephen Tusa downgrades Vertiv Holdings (NYSE:VRT) from Overweight to Neutral and announces $25 price target.